| Identification | Back Directory | [Name]
1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)- | [CAS]
2050057-56-0 | [Synonyms]
Upadacitinib hemihydrate
1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)- | [Molecular Formula]
C17H21F3N6O2 | [MOL File]
2050057-56-0.mol | [Molecular Weight]
398.39 |
| Hazard Information | Back Directory | [Clinical Use]
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Each prolonged-release tablet (RINVOQ 15 mg prolonged-release tablets.) contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib. |
|
| Company Name: |
Svak Life Sciences
|
| Tel: |
+91-9963463333 +91-9705383777 |
| Website: |
www.svaklifesciences.com |
|